XOMA Limited: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-24

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

XOMA is a biopharmaceutical company focusing on the discovery and development of therapeutic antibodies for the treatment of cancer and immune diseases. The company has a broad technology platform and a fully integrated product development infrastructure for antibodies and other biologics.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    XOMA's technological platform makes the company unique from its competitors. The company's marketed product, Lucentis was developed using its BCE technology and XOMA 052 is the first candidate being developed using another proprietary technology, Human Engineered (HE) technology.

    The company derives its revenues from contract, licensing, collaboration and royalties. These include upfront and milestone payments related to the outlicensing agreement with Merck & Co as well as from contracts entered with SPRI, Taligen, AVEO and NIAID, Genentech and Novartis.

    During 2006-2010, XOMA's revenues are expected to grow at a CAGR of 39% rising from $29 million to $110 million, over the period 2006-2010, XOMA's biggest contributor to sales growth out to 2010 will be from contract, license and collaboration, forecasted to grow at a CAGR of 43% from $19 million in 2006 to $81 million in 2010.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: xoma competitor j charles mark pharmaceuticals white fisher 629 employees

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.